New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review) - HAL-SHS - Sciences de l'Homme et de la Société
Article Dans Une Revue Molecular and Clinical Oncology Année : 2023

New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review)

Résumé

Nuclear medicine is an essential part of prostate cancer management concerning initial staging, patient’s follow-up and even therapy. PSMA is a glutamate carboxypeptidase II transmembrane glycoprotein expressed by 80% of prostatic cells. Its interest resides in its specificity for prostatic tissue. The use of 68GaPSMA PET/CT in the context of disease staging is thus well-established and recommended, especially for high-risk disease with metastases and lymph node involvement. However, the risk of false positives raises questions about its place in the management of patients with prostate cancer. The purpose of this article is to recall the place of PET-PSMA in the care of patients with prostate cancer but also its limits of use.

Dates et versions

halshs-04565524 , version 1 (01-05-2024)

Licence

Identifiants

Citer

Hélène Simon, Daniel Henkel, Paul Chiron, Carole Helissey. New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review). Molecular and Clinical Oncology, 2023, 19 (1), pp.51. ⟨10.3892/mco.2023.2647⟩. ⟨halshs-04565524⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

More